Medartis Holding AG (MED) AI Stock Analysis

• Market Cap: CHF1.19B
• Dividend Yield: N/A
• Average Volume (3M): 7.01K
• Price to Earnings (P/E): 282.8
• Beta (1Y): 1.09
• Revenue Growth: 7.29%
• EPS Growth: -112.70%
• Country: CH
• Employees: 816
• Sector: Healthcare
• Sector Strength: 46
• Industry: Medical - Devices
• EPS (TTM): -0.12
• Shares Outstanding: 13,618,050
• 10 Day Avg. Volume: 11,936
• 30 Day Avg. Volume: 7,007
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: CHF88.50
• Price Target Upside: -2.75% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 2

• Rating: 61 Neutral
• Price Target: CHF87.00 ▼(-4.40% Downside)

Medartis Holding AG's overall score is driven by strong financial performance and positive technical trends. However, the valuation is significantly impacted by a negative P/E ratio and lack of dividend yield, which weigh down the overall attractiveness of the stock.

Positive Factors

Acquisition Strategy

The acquisition of a 51% stake in NeoOrtho is viewed favorably, offering a multi-tiered product approach in the Brazilian market.

Market Adaptation

Investors have a favorable impression of Medartis's focus on adapting to local markets and differentiating the 'new' Medartis from the 'old'.

Product Portfolio

The emphasis on Upper Extremities with a complete portfolio and the Keri Touch thumb device is seen as a strategic move.

Negative Factors

Financial Guidance

Top-line FY25 guidance is approximately 7-9% below consensus, causing disappointment despite EBITDA being in line.

Operational Issues

Management referred to issues with client engagement/onboarding, set retrieval/line filling, and unachievable targets in the U.S.

US Market Challenges

The US market is undergoing a strategic review, with 2024 being a transition year, indicating challenges in this key region for future success.

Medartis Holding AG Business Overview & Revenue Model

Company Description

Medartis Holding AG (MED) is a leading Swiss company specializing in the development, manufacturing, and sale of innovative medical devices, specifically for the fields of osteosynthesis. The company's primary focus is on providing high-quality implants and instruments for the surgical fixation of bone fractures and osteotomies. Medartis operates primarily within the healthcare and medical technology sectors, striving to enhance surgical outcomes and patient recovery through its advanced product offerings.

How the Company Makes Money

Medartis Holding AG generates revenue through the sale of its specialized medical devices and related instruments. The company markets a comprehensive portfolio of implants and surgical tools designed for cranial, upper, and lower extremity applications. Revenue streams are primarily derived from direct sales to hospitals, clinics, and healthcare providers, as well as through partnerships and distribution agreements with other medical technology companies and distributors globally. Medartis leverages its strong brand reputation, innovative product offerings, and extensive distribution network to maintain a steady stream of income. Additionally, the company invests in research and development to continuously improve its product line, which helps in sustaining competitive advantage and driving sales growth.

Medartis Holding AG Financial Statement Overview

Summary

Medartis Holding AG shows strong revenue growth and financial stability with a robust gross profit margin and improved cash flow. However, low net profit margins and modest return on equity indicate room for operational improvements.

Income Statement

Medartis Holding AG demonstrates a strong revenue growth trajectory with a 6% increase from 2023 to 2024. The gross profit margin has remained robust at approximately 79.5% in 2024. However, the net profit margin remains relatively low at 1.57%, indicating potential challenges in cost management or operational efficiency. The EBIT and EBITDA margins are moderate at 3.5% and 13.4% respectively, showing room for improvement in operational leverage.

Balance Sheet

The company maintains a healthy balance sheet with a favorable equity ratio of 58.6% in 2024, indicating a strong capital structure. The debt-to-equity ratio is at a manageable 0.45, reflecting prudent financial leverage. Return on equity is modest at 1.31%, suggesting potential underutilization of shareholder funds. Overall, the financial position is stable with potential for enhanced returns.

Cash Flow

Medartis Holding AG exhibits a significant improvement in free cash flow, growing from CHF 1.17 million in 2023 to CHF 21 million in 2024. The operating cash flow to net income ratio is strong, highlighting efficient cash conversion from profits. The free cash flow to net income ratio is robust at 5.95, underscoring efficient capital management. However, consistent positive cash flow generation remains critical for sustained financial health.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	224.83M	212.01M	182.82M	159.88M	127.65M
Gross Profit	178.68M	167.57M	135.39M	121.57M	93.89M
EBITDA	30.18M	24.69M	16.24M	26.10M	13.96M
Net Income	3.53M	619.00K	-5.78M	6.84M	-943.57K
Balance Sheet
Total Assets	459.96M	349.53M	327.89M	298.18M	282.79M
Cash, Cash Equivalents and Short-Term Investments	138.69M	25.20M	20.60M	82.64M	82.73M
Total Debt	120.29M	26.92M	52.04M	24.07M	27.18M
Total Liabilities	190.31M	94.58M	90.11M	74.18M	69.76M
Stockholders Equity	269.65M	254.96M	237.78M	224.00M	213.04M
Cash Flow
Free Cash Flow	21.00M	1.17M	-22.72M	10.57M	-455.29K
Operating Cash Flow	28.17M	19.96M	-3.93M	20.95M	12.61M
Investing Cash Flow	-19.06M	-37.83M	-52.91M	-15.87M	-22.86M
Financing Cash Flow	104.48M	23.21M	-3.90M	-4.78M	-4.73M

Medartis Holding AG Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 91.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:MED, the sentiment is Positive. The current price of 91 is above the 20-day moving average (MA) of 81.68, above the 50-day MA of 81.18, and above the 200-day MA of 71.20, indicating a bullish trend. The MACD of 1.87 indicates Negative momentum. The RSI at 68.08 is Neutral, neither overbought nor oversold. The STOCH value of 95.43 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:MED.

Medartis Holding AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SOON	72 Outperform	CHF13.40B	25.48		1.90%	6.58%	-10.02%
BSLN	65 Neutral	CHF573.64M	7.88		―	58.51%	―
MED	61 Neutral	CHF1.19B	282.78		―	7.29%	-112.70%
Sector *	51 Neutral	$7.85B	-0.18	-40.01%	2.28%	22.97%	-2.05%
MEDGF	―	$3.63B	45.33	20.81%	0.45%	―	―
SGFEF	―	$4.72B	28.15	15.79%	0.43%	―	―
TCHBF	―	$2.65B	36.63	4.57%	1.79%	―	―

Medartis Holding AG Corporate Events

Medartis to Present 2025 Half-Year Results via Webcast

Medartis Holding AG has announced a webcast presentation of its half-year results for 2025, scheduled for August 19, 2025. The event will feature presentations by CEO Matthias Schupp and CFO Dirk Kirsten, and will be available for viewing via MS Teams. This announcement signifies Medartis’s commitment to transparency and engagement with stakeholders, providing insights into its financial performance and strategic direction.

The most recent analyst rating on (CH:MED) stock is a Buy with a CHF86.00 price target. To see the full list of analyst forecasts on Medartis Holding AG stock, see the CH:MED Stock Forecast page.

Medartis Completes Acquisition of KeriMedical to Bolster Hand Surgery Portfolio

Medartis Holding AG has acquired the remaining 53% of shares in KeriMedical, a company specializing in hand and wrist surgery implants, for CHF 99 million. This acquisition, following the FDA approval of KeriMedical’s TOUCH thumb prosthesis, strengthens Medartis’ position in joint replacement and expands its network of surgeons, with an immediate positive impact on sales growth and EBITDA margin. KeriMedical will continue as an independent brand within Medartis, retaining its development and marketing teams, while co-founders Dougal Bendjaballah and Bernard Prandi remain on the board. The acquisition enhances Medartis’ competencies in hand and wrist surgery, aligning with its strategic goals and expanding its market reach, particularly in Europe, the US, and Australia.

The most recent analyst rating on (CH:MED) stock is a Buy with a CHF86.00 price target. To see the full list of analyst forecasts on Medartis Holding AG stock, see the CH:MED Stock Forecast page.